Your browser doesn't support javascript.
loading
Assessing the stability of lamotrigine dispersible/chewable tablets when stored in blister punch cards.
Loscertales, Héctor R; Modamio, Pilar; Lastra, Cecilia F; Mariño, Eduardo L.
Afiliación
  • Loscertales HR; a Clinical Pharmacy and Pharmacotherapy Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences , University of Barcelona , Barcelona , Spain.
  • Modamio P; a Clinical Pharmacy and Pharmacotherapy Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences , University of Barcelona , Barcelona , Spain.
  • Lastra CF; a Clinical Pharmacy and Pharmacotherapy Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences , University of Barcelona , Barcelona , Spain.
  • Mariño EL; a Clinical Pharmacy and Pharmacotherapy Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences , University of Barcelona , Barcelona , Spain.
Curr Med Res Opin ; 33(5): 949-953, 2017 05.
Article en En | MEDLINE | ID: mdl-28277872
OBJECTIVES: To determine the stability of lamotrigine dispersible/chewable tablets (DCTs) when stored in blister punch cards (BPCs). METHODS: Lamotrigine 100 mg DCTs were randomly repackaged into a US Pharmacopeia Class A 1 week cold-sealed BPC. Chemical and physical stability were evaluated over a 60 day period, in controlled conditions corresponding to Climatic Zones I/II (25 °C ± 2 °C; 60% ± 5% relative humidity). At scheduled times, various tests were performed on tablets in their primary packaging (reference samples) and on tablets repackaged (BPC samples). A validated high-performance liquid chromatography method adapted from the US Pharmacopeia was used to quantify lamotrigine. RESULTS: Lamotrigine content remained within the US Pharmacopeia acceptance range of 90%-110% during the 60 day study period and there were no significant changes compared with reference samples (p = .386). The increase of weight and the reduction of hardness of the repackaged tablets did not affect their dissolution profiles, and no change in appearance was observed. All tests complied with the compendial requirements of the pharmaceutical physical tests. CONCLUSIONS: Although changes in hardness after 14 days have not impacted on outcomes in terms of compliance with compendial requirements, a cautious recommendation would probably be a BPC storage of lamotrigine DCT of up to 14 days after repackaging.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Triazinas / Cromatografía Líquida de Alta Presión / Embalaje de Medicamentos Idioma: En Revista: Curr Med Res Opin Año: 2017 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Triazinas / Cromatografía Líquida de Alta Presión / Embalaje de Medicamentos Idioma: En Revista: Curr Med Res Opin Año: 2017 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido